

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597963
	Filing Date		2006-08-15
	First Named Inventor	Veronesi	
	Art Unit	1611	
	Examiner Name	Charlesworth E. Rae	
	Attorney Docket Number	IPU1954-009	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3931141		1976-01-06	Wissmann et al.	
	2	4001327		1977-01-05	Lucchesi	
	3	4236509		1980-12-02	Takahashi et al.	
	4	4368193		1983-01-11	Argoudelis et al.	
	5	4423067		1983-12-27	Skuballa et al.	
	6	4464466		1984-08-07	Argoudelis et al.	
	7	4613500		1986-09-23	Suzuki et al.	
	8	4832954		1989-05-23	Sato et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10597963
Filing Date		2006-08-15
First Named Inventor	Veronesi	
Art Unit		1611
Examiner Name	Charlesworth E. Rae	
Attorney Docket Number		IPU1954-009

	9	5057317		1991-10-15	lida	
	10	5059587		1991-10-22	Yamamoto et al.	
	11	5080906		1992-01-14	Carenzi et al.	
	12	5112604		1992-05-12	Beaurline et al.	
	13	5188840		1993-02-23	lida et al.	
	14	5580576		1996-12-03	Veronesi et al.	
	15	5582591		1996-12-10	Cheikh	
	16	5733569		1998-03-31	Azria et al.	
	17	5759565		1998-06-02	Azria et al.	
	18	5776885		1998-07-07	Orsolini et al.	
	19	6333044	B1	2001-12-25	Santus et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10597963
Filing Date		2006-08-15
First Named Inventor	Veronesi	
Art Unit		1611
Examiner Name	Charlesworth E. Rae	
Attorney Docket Number		IPU1954-009

	20	6376461	B1	2002-04-23	Igari et al.	
	21	6440392	B1	2002-08-27	Stern	
	22	6500808	B2	2002-12-31	Killam	
	23	6577947	B1	2003-06-10	Kronfeld et al.	
	24	6623732	B1	2003-09-23	Ma	
	25	6638915	B1	2003-10-28	Killam	
	26	6734162	B2	2004-05-11	Van Antwerp et al.	
	27	7022687	B1	2006-04-04	Szelenyi et al.	
	28	7045323	B2	2006-05-16	Ansovini	
	29	7348360	B2	2008-03-25	Hensley et al.	
	30	7572599	B2	2009-08-11	Lee et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597963
Filing Date	2006-08-15
First Named Inventor	Veronesi
Art Unit	1611
Examiner Name	Charlesworth E. Rae
Attorney Docket Number	IPU1954-009

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040033260	A1	2004-02-19	Rennie et al.	
	2	20040138118	A1	2004-07-15	Wolfman et al.	
	3	20040224890	A1	2004-11-11	Quay et al.	
	4	20050158247	A1	2005-07-21	Veronesi et al.	
	5	20060275280	A1	2006-12-07	Lee et al.	
	6	20070265337	A1	2007-11-15	Hensley et al.	
	7	20080085298	A1	2008-04-10	Pohl et al.	
	8	20090035260	A1	2009-02-05	Veronesi et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597963
Filing Date	2006-08-15
First Named Inventor	Veronesi
Art Unit	1611
Examiner Name	Charlesworth E. Rae
Attorney Docket Number	IPU1954-009

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0094157	EP	A1	1983-11-16	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	2	0468182	EP	A1	1992-01-29	Sclavo S.p.A.		<input type="checkbox"/>
	3	1539318	GB		1979-01-31	Ferring AB		<input type="checkbox"/>
	4	01243742	IT	B	1994-06-21	Istituto Biochimico Nazionale Savio S.r.l.	In Italian, English abstract attached	<input checked="" type="checkbox"/>
	5	55-55120	JP	A	1980-04-22	Sandoz AG	In Japanese, English abstract attached	<input checked="" type="checkbox"/>
	6	55-66517	JP	A	1980-05-20	Sandoz AG	In Japanese, relevance discussed in paragraph [009] of the written specification	<input type="checkbox"/>
	7	2007/126865	WO	A2	2007-11-08	Patrin Pharma		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	BERGQUIST, C. ET AL., Intranasal Gonadotropin-Releasing Hormone Agonist As A Contraceptive Agent, The Lancet, August 4, 1979, pp. 215-216, 11(8136), Boston, Massachusetts and London.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597963
Filing Date	2006-08-15
First Named Inventor	Veronesi
Art Unit	1611
Examiner Name	Charlesworth E. Rae
Attorney Docket Number	IPU1954-009

2	BRUYNZEEL, D.P. ET AL., Contact dermatitis to lauryl pyridinium chloride and benzoxonium chloride, Contact Dermatitis, Short Communications, 1987, pp. 41-42, 17, Blackwell Munksgaard, Copenhagen, Denmark.	<input type="checkbox"/>
3	BUDAVARI, S. ET AL., The Merck Index, 1996, pp. 2146, Twelfth Edition, Merck & Co., Inc., Whitehouse Station, New Jersey.	<input type="checkbox"/>
4	CHEVANCE, L.G. ET AL., Etude Des Rythmes Du Battement Ciliaire, Acta Oto-Laryngologica, July 1970, pp. 16-28, 70(1), Taylor & Francis AB, Stockholm, Sweden.	<input type="checkbox"/>
5	DUA, R. ET AL., The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits, International Journal Of Pharmaceutics, 1997, pp. 233-242, 147, Elsevier BV, Amsterdam, Netherlands.	<input type="checkbox"/>
6	EL-SAYED, G.M., The role of tromethamine as a dissolution and bioavailability enhancer of oral glibenclamide, STP Pharma Sciences, 1998, pp. 169-173, 8(3), Editions de sante, Paris, France.	<input type="checkbox"/>
7	FELBER, J.P. ET AL., Administration by Nasal Spray of an 18 Amino Acid Synthetic Polypeptide with Corticotropic Action, Experientia, November 15, 1969, pp. 1195-1196, 25(11).	<input checked="" type="checkbox"/>
8	FISHER, A.A., Allergic Contact Dermatitis and Conjunctivitis from Benzalkonium Chloride, Cutis, May 1987, pp. 381-383, 39, Quadrant HealthCom, Chatham, New Jersey.	<input type="checkbox"/>
9	GENNSER, G. ET AL., Intranasal Administration of Luteinising-Hormone Releasing Factor, The Lancet, May 4, 1974, pp. 865-866, 1(7862), Boston, Massachusetts and London.	<input type="checkbox"/>
10	GREENBERG, S.B. ET AL., Antiviral Activity of Intranasally Applied Human Leukocyte Interferon, Antimicrobial Agents and Chemotherapy, October 1978, pp. 596-600, 14(4), American Society for Microbiology, Washington, D.C.	<input type="checkbox"/>
11	JAPAN DIABETES SOCIETY, Summary, 1974, pp. 237 and 253, 17, Journal of the Diabetic Society, Tokyo, Japan.	<input type="checkbox"/>
12	LEMP, M.A. ET AL., Toxic Endothelial Degeneration in Ocular Surface Disease Treated With Topical Medications Containing Benzalkonium Chloride, American Journal of Ophthalmology, June 1988, pp. 670-673, 105(6), Elsevier Inc, New York, New York.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597963
Filing Date	2006-08-15
First Named Inventor	Veronesi
Art Unit	1611
Examiner Name	Charlesworth E. Rae
Attorney Docket Number	IPU1954-009

13	MOREN, F. ET AL., Aerosols in Medicine, Principles, Diagnosis and Therapy, 1993, pp. 346, Second, revised edition, Elsevier Science Publishers B.V., Amsterdam, Netherlands.	<input type="checkbox"/>
14	NISHIHATA, T. ET AL., Enhanced rectal absorption of insulin and heparin in rats in the presence of non-surfactant adjuvants, Journal of Pharmacy and Pharmacology, Communications, 1981, pp. 334-335, Pharmaceutical Press, London, United Kingdom.	<input type="checkbox"/>
15	PONTIROLI, A.E. ET AL., Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects, British Medical Journal, Papers and Short Reports, January 30, 1982, pp. 303-306, 284, BMJ Publishing Group, London, United Kingdom.	<input type="checkbox"/>
16	THE EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS, Committee For Proprietary Medicinal Products, Note For Guidance On In-Use Stability Testing Of Human Medicinal Products, March 1, 2001, 3 pages, CPMP/QWP/2934/99, London, United Kingdom.	<input type="checkbox"/>
17	WIGLEY, F.M. ET AL., Insulin Across Respiratory Mucosae by Aerosol Delivery, Diabetes, August 1971, pp. 552-556, 20(8), American Diabetes Association, Alexandria, Virginia.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.